SCHEMBL6189307

SCHEMBL6189307

Cn1c(=O)[nH]c(=O)c2[nH]c(=S)[nH]c21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.45
KDM4E B2RXH2 2/20 0.45
MAPT P10636 2/20 0.45
HPGD P15428 2/20 0.45
HSD17B10 Q99714 2/20 0.45
ALOX15 P16050 1/20 0.45
ALOX12 P18054 1/20 0.45
KDM1A O60341 1/20 0.45
GAA P10253 2/20 0.43
PKM P14618 1/20 0.43
BRPF1 P55201 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MAPK10 P53779 1/20 0.41
KMT2A Q03164 3/20 0.39
RXFP1 Q9HBX9 1/20 0.38
MEN1 O00255 2/20 0.38
BRAF P15056 1/20 0.38
DAO P14920 1/20 0.34
CSNK2A2 P19784 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL133905 0.79 HPGD (0.40) ALDH1A1KDM4EMAPTHPGDHSD17B10
SCHEMBL2893544 0.75 CSNK2A2 (0.39) ALDH1A1KDM4EMAPTHPGDHSD17B10
Uric Acid SCHEMBL20141715 0.68 GDA (0.57) ALDH1A1KDM4EMAPTHPGDHSD17B10
SCHEMBL6189308 0.68 HSD17B10 (0.44) ALDH1A1KDM4EMAPTHPGDHSD17B10
SCHEMBL10957749 0.67 CSNK2A2 (0.43) ALDH1A1KDM4EMAPTHPGDHSD17B10
SCHEMBL21594813 0.66 ADORA2B (0.46) ALDH1A1KDM4EMAPTHPGDHSD17B10
SCHEMBL924091 0.66 ALDH1A1 (0.55) ALDH1A1KDM4EMAPTHPGDHSD17B10
SCHEMBL23777294 0.63 KDM4E (0.38) ALDH1A1KDM4EMAPTHPGDHSD17B10
SCHEMBL2787496 0.61 ALDH1A1 (1.00) ALDH1A1KDM4EMAPTHPGDHSD17B10
SCHEMBL8317662 0.59 RXFP1 (0.45) ALDH1A1KDM4EMAPTGAABRPF1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1193257-B1 Compounds for ceramide-mediated signal transduction UNIV CALIFORNIA (US) 2005-09-07 EP disclosed
EP-0986561-B1 COMPOUNDS FOR INHIBITION OF CERAMIDE-MEDIATED SIGNAL TRANSDUCTION UNIV CALIFORNIA (US) 2005-07-27 EP disclosed
US-6562819-B2 Antiinflammatory agents; antiproliferative agents THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2003-05-13 US disclosed
US-20020165202-A1 Compounds for inhibition of ceramide-mediated signal transduction THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2002-11-07 US disclosed
EP-0801568-B1 COMPOUNDS FOR INHIBITION OF CERAMIDE-MEDIATED SIGNAL TRANSDUCTION UNIV CALIFORNIA (US) 2002-07-17 EP disclosed
EP-1193257-A2 Compounds for ceramide-mediated signal transduction THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2002-04-03 EP disclosed
US-6323201-B1 ANTIINFLAMMATORY AGENTS, ANTIPROLIFERATION AGENTS AND ENZYME INHIBITORS OF PHOSPHODIESTERASE THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2001-11-27 US disclosed
EP-0986561-A4 COMPOUNDS FOR INHIBITION OF CERAMIDE-MEDIATED SIGNAL TRANSDUCTION UNIV CALIFORNIA (US) 2001-06-13 EP disclosed
EP-1091960-A1 BIFUNCTIONAL ANTAGONISTS OF CYTOKINE-SENSITIVE PROTEIN KINASE ACTIVATION CASCADES AND METHODS FOR USE AS ANTI-INFLAMMATORY AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2001-04-18 EP disclosed
EP-0986561-A1 COMPOUNDS FOR INHIBITION OF CERAMIDE-MEDIATED SIGNAL TRANSDUCTION The Regents of the University of California (US) 2000-03-22 EP disclosed
WO-2000000491-A1 BIFUNCTIONAL ANTAGONISTS OF CYTOKINE-SENSITIVE PROTEIN KINASE ACTIVATION CASCADES AND METHODS FOR USE AS ANTI-INFLAMMATORY AGENTS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2000-01-06 WO disclosed
US-5843943-A Compounds for inhibition of ceramide-mediated signal transduction THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-12-01 US disclosed
WO-1998052948-A1 COMPOUNDS FOR INHIBITION OF CERAMIDE-MEDIATED SIGNAL TRANSDUCTION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1998-11-26 WO disclosed
EP-0801568-A4 COMPOUNDS FOR INHIBITION OF CERAMIDE-MEDIATED SIGNAL TRANSDUCTION UNIV CALIFORNIA (US) 1998-02-25 EP disclosed
EP-0801568-A1 COMPOUNDS FOR INHIBITION OF CERAMIDE-MEDIATED SIGNAL TRANSDUCTION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1997-10-22 EP disclosed
WO-1996020710-A1 COMPOUNDS FOR INHIBITION OF CERAMIDE-MEDIATED SIGNAL TRANSDUCTION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1996-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020165202-A1 Compounds for inhibition of ceramide-mediated signal transduction SMPD1, CERT1, SMPD3 ALDH1A1 3282/4885KDM4E 2809/4885MAPT 4241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.